ELV logo

Elevance Health, Inc. Stock Price

NYSE:ELV Community·US$79.5b Market Cap
  • 4 Narratives written by author
  • 0 Comments on narratives written by author
  • 179 Fair Values set on narratives written by author

ELV Share Price Performance

US$351.42
-157.60 (-30.96%)
29.1% undervalued intrinsic discount
US$495.70
Fair Value
US$351.42
-157.60 (-30.96%)
30.7% undervalued intrinsic discount
US$507.00
Fair Value
Price US$351.42
AnalystHighTarget US$507.00
AnalystConsensusTarget US$361.39
AnalystLowTarget US$297.00

ELV Community Narratives

AnalystHighTarget·
Fair Value US$495.7 29.1% undervalued intrinsic discount

Aging Trends And Digital Integration Will Expand Managed Care Markets

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystConsensusTarget·
Fair Value US$361.39 2.8% undervalued intrinsic discount

AI-Enabled Analytics And Value-Based Care Will Ensure Future Stability

0users have liked this narrative
0users have commented on this narrative
102users have followed this narrative
AnalystLowTarget·
Fair Value US$297 18.3% overvalued intrinsic discount

ACA And Medicaid Will Squeeze Margins Though Tech Will Aid

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative

ELV Community Fair Values

Recent ELV News & Updates

Positive Sentiment Still Eludes Elevance Health, Inc. (NYSE:ELV) Following 25% Share Price Slump

Jul 29
Positive Sentiment Still Eludes Elevance Health, Inc. (NYSE:ELV) Following 25% Share Price Slump

Elevance Health, Inc. Key Details

US$189.3b

Revenue

US$138.5b

Cost of Revenue

US$50.8b

Gross Profit

US$45.4b

Other Expenses

US$5.4b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 21, 2025
Earnings per share (EPS)
23.80
Gross Margin
26.84%
Net Profit Margin
2.83%
Debt/Equity Ratio
68.8%

Elevance Health, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet established dividend payer.

0 Risks
3 Rewards

About ELV

Founded
2001
Employees
104200
CEO
Gail Boudreaux
WebsiteView website
www.elevancehealth.com

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. It operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The company offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. It also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, the company provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. It provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -1.3%
  • 3 Months: 7.3%
  • 1 Year: 14.4%
  • Year to Date: 13.5%
Over the last 7 days, the market has dropped 1.3%, driven by a pullback of 2.1% in the Financials sector. In the last year, the market is actually up 14%. Earnings are forecast to grow by 15% annually. Market details ›